Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Idarubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.98 |
| ▸ | ECE1 | P42892 | 1/20 | 1.00 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 10/20 | 0.98 |
| ▸ | THRB | P10828 | 10/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.98 |
| ▸ | BLM | P54132 | 9/20 | 0.98 |
| ▸ | RECQL | P46063 | 8/20 | 0.98 |
| ▸ | MAPT | P10636 | 7/20 | 0.98 |
| ▸ | BRCA1 | P38398 | 7/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.98 |
| ▸ | HTT | P42858 | 5/20 | 0.98 |
| ▸ | USP2 | O75604 | 5/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.98 |
| ▸ | S100A4 | P26447 | 5/20 | 0.98 |
| ▸ | STAT6 | P42226 | 5/20 | 0.98 |
| ▸ | NPC1 | O15118 | 4/20 | 0.98 |
| ▸ | RAB9A | P51151 | 4/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Idarubicin SCHEMBL454665 | 1.00 | ECE1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL29367370 | 1.00 | ECE1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL5323218 | 1.00 | ECE1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL20838939 | 0.99 | ECE1 (0.98) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL16606206 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL7029978 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL16609956 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL20541733 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL15159345 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL12257447 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 27171 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102563-A1 | DISUBSTITUTED PYRIMIDOPYRROLE ANALOG AND USE THEREOF | 深圳湾实验室坪山生物医药研发转化中心 | 2026-05-21 | — | — | WO | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4727933-A1 | COMBINATION THERAPY METHODS FOR TREATING TP53-Y220C MUTANT AND TP53 WILDTYPE LEUKEMIAS | Board of Regents, The University of Texas System (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-12569575-B2 | Radiopaque particle compositions and uses thereof | GUSTAVE ROUSSY TRANSFERT (FR) | 2026-03-10 | — | — | US | claimed |
| EP-4694915-A1 | TREATMENT OF HAEMATOLOGICAL CANCER | STERLING IP PTE LTD (SG) | 2026-02-18 | — | — | EP | claimed |
| EP-4694914-A1 | INHIBITION OF: STROMA/CANCER CELL CROSS-TALK &/OR STROMA GENERATED RESISTANCE TO TREATMENT | STERLING IP PTE LTD (SG) | 2026-02-18 | — | — | EP | claimed |
| US-12527836-B2 | Gla domains as targeting agents | GLAdiator Biosciences, Inc. (US) | 2026-01-20 | — | — | US | claimed |
| US-20010018919-A1 | Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response | DIMENSIONAL DOSING SYSTEMS, INCORPORATED | 2001-09-06 | — | — | US | claimed |
| US-6284738-B1 | EPIRUBICIN HYDROCHLORIDE | PHARMACIA & UPJOHN COMPANY | 2001-09-04 | — | — | US | claimed |
| WO-2001009375-A2 | INDUCIBLE SCREEN FOR DRUG DISCOVERY | UNIVERSITY COLLEGE LONDON (GB) | 2001-02-08 | — | — | WO | claimed |
| US-6107285-A | SEALED CONTAINER; ANTITUMOR AGENT | PHARMACIA & UPJOHN COMPANY (US) | 2000-08-22 | — | — | US | claimed |
| CN-1261803-A | Antioxidant enhancement of therapy for hyperproliferative conditions | ATHEROGENICS INC (US) | 2000-08-02 | — | — | CN | claimed |
| CN-1250375-A | Pharmaceutical composition containing shark cartilage extract and antitumor agent for treating tumor | AETERNA LAB INC (CA) | 2000-04-12 | — | — | CN | claimed |
| EP-0967987-A1 | COMPOSITIONS FOR TREATING TUMORS CONTAINING SHARK CARTILAGE EXTRACTS AND ANTI-NEOPLASTIC AGENTS | LES LABORATOIRES AETERNA INC. (CA) | 2000-01-05 | — | — | EP | claimed |
| WO-1998040088-A1 | COMPOSITIONS FOR TREATING TUMORS CONTAINING SHARK CARTILAGE EXTRACTS AND ANTI-NEOPLASTIC AGENTS | LES LABORATOIRES AETERNA INC. (CA) | 1998-09-17 | — | — | WO | claimed |
| US-5736129-A | Flow cytometric pharmacosensitivity assay and method of cancer treatment | SHAKER CORPORATION, A DELAWARE CORPORATION | 1998-04-07 | — | — | US | claimed |
| WO-1997019189-A1 | FLOW CYTOMETRIC PHARMACOSENSITIVITY ASSAY AND METHOD OF CANCER TREATMENT | MEDENICA RAJKO D (US) | 1997-05-29 | — | — | WO | claimed |